Evaluating the effectiveness and safety of Dalbavancin for infection treatment
Official title: Efficacy and Safety of Dalbavancin As Suppressive Therapy
Run by Hospices Civils de Lyon · NCT06899906 · Data updated 2026-11-12
This study is testing if Dalbavancin, a long-lasting antibiotic, is safe and effective for people who have been on other antibiotics for their infections.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 33 (estimated) |
| Sponsor | Hospices Civils de Lyon Academic / other |
| Locations | 1 site (France, Lyon) |
| Status | Recruiting |
| Started | October 1, 2024 |
| Main results expected | March 1, 2025 |
| Study ends | May 1, 2025 |
| Registry record updated | March 28, 2025 |
| Trial ID | NCT06899906 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults over 18 who have received Dalbavancin as part of their treatment for acute or chronic infections.
✕Probably not a fit
Patients under 18 years old or those who received Dalbavancin for purposes other than SAT will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study assesses the efficacy and safety of Dalbavancin, a semi-synthetic antibiotic, in patients who have received suppressive antibiotic therapy (SAT) for acute or chronic infections. The study focuses on patients treated between July 2019 and December 2024, gathering demographic and clinical characteristics at baseline. Dalbavancin is known for its long half-life and ability to penetrate various tissues, making it a promising option for treating Gram-positive infections.
Why it matters
Potential benefit: If successful, this study could provide insights into the effectiveness of Dalbavancin as a long-term treatment option for patients with difficult-to-treat infections.
How similar studies have gone: While there have been studies on Dalbavancin, this specific observational approach focusing on SAT is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * \> 18 years * Patients received SAT with DAL for acute or chronic infections (defined as a long-standing infection due to a previously uneradicated pathogen, following unsuccessful antibiotic or surgical treatments) between July 2019 and December 2024 * Patient who was informed and did not object to participating in the study Exclusion Criteria: * -\< 18 years * Subjects who received DAL not for SAT purposes
Where it's running
-
Hcl
France, Lyon, France Recruiting
Study contacts
- Study coordinator: Tristan Ferry
- Email: Tristan.ferry@chu-lyon.fr
- Phone: + 33 4 72 07 24 81
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.